Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia.

Literature DB >> 28503240

Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia.

Gregory W Hosier¹, Naji J Touma¹.

Abstract

Entities: Chemical Disease Species

Year: 2017 PMID： 28503240 PMCID： PMC5426947 DOI： 10.5489/cuaj.4316

Source DB: PubMed Journal: Can Urol Assoc J ISSN： 1911-6470 Impact factor: 1.862

× No keyword cloud information.

12 in total

Review 1. A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.

Authors: Carolyn Owen; Isabelle Bence-Bruckler; Inès Chamakhi; Cynthia Toze; Wissam Assaily; Anna Christofides; Sue Robinson
Journal: Clin Lymphoma Myeloma Leuk Date: 2015-03-26

Review 2. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.

Authors: Maria I Carlo; Martin H Voss; Robert J Motzer
Journal: Nat Rev Urol Date: 2016-06-21 Impact factor: 14.432

3. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.

Authors: Idit Sagiv-Barfi; Holbrook E K Kohrt; Debra K Czerwinski; Patrick P Ng; Betty Y Chang; Ronald Levy
Journal: Proc Natl Acad Sci U S A Date: 2015-02-17 Impact factor: 11.205

Review 4. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.

Authors: Chung-Shien Lee; Mohammad A Rattu; Sara S Kim
Journal: J Oncol Pharm Pract Date: 2014-11-25 Impact factor: 1.809

Review 5. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.

Authors: Esther S Kim; Sohita Dhillon
Journal: Drugs Date: 2015-05 Impact factor: 9.546

6. Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors: Sabine Ponader; Jan A Burger
Journal: J Clin Oncol Date: 2014-04-28 Impact factor: 44.544

7. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors: Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245

Review 8. Immune Checkpoint Therapy in Renal Cell Carcinoma.

Authors: Chung-Han Lee; Robert J Motzer
Journal: Cancer J Date: 2016 Mar-Apr Impact factor: 3.360

Review 9. Targets for Ibrutinib Beyond B Cell Malignancies.

Authors: A Berglöf; A Hamasy; S Meinke; M Palma; A Krstic; R Månsson; E Kimby; A Österborg; C I E Smith
Journal: Scand J Immunol Date: 2015-09 Impact factor: 3.487

10. Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.

Authors: Steven D Schutt; Jianing Fu; Hung Nguyen; David Bastian; Jessica Heinrichs; Yongxia Wu; Chen Liu; Daniel G McDonald; Joseph Pidala; Xue-Zhong Yu
Journal: PLoS One Date: 2015-09-08 Impact factor: 3.240

3 in total